Search our website

Press Releases

VBI Vaccines Announces U.S. FDA Acceptance of BLA Filing for VBI’s 3-Antigen Prophylactic Hepatitis B Vaccine
February 2nd, 2021
VBI Vaccines Announces Progress of Coronavirus Vaccine Program
January 21st, 2021
VBI Vaccines Announces Publication of Results from a Phase 4 Study of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine in Vaccine
January 15th, 2021
VBI Vaccines Announces European Medicines Agency Acceptance of Marketing Authorization Application (MAA) for 3-Antigen Prophylactic Hepatitis B Vaccine
December 23rd, 2020
VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B Vaccine
December 7th, 2020
VBI Vaccines to Discuss Hepatitis B Portfolio in Virtual Fireside Chat Hosted by Raymond James
December 2nd, 2020
VBI Vaccines Announces Submission of Biologics License Application to FDA for 3-Antigen Prophylactic Hepatitis B Vaccine
December 1st, 2020
VBI Vaccines Announces Submission of Marketing Authorization Application for 3-Antigen Prophylactic Hepatitis B Vaccine to the European Medicines Agency
November 23rd, 2020
VBI Vaccines Announces Positive Interim Phase 2a Data from VBI-1901 in Recurrent GBM
November 19th, 2020
VBI Vaccines Announces Positive Interim Phase 1b/2a Data for Hepatitis B Immunotherapeutic in Patients with Chronic Infection
November 18th, 2020
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at The Liver Meeting® 2020
November 13th, 2020
VBI Vaccines Announces e-Poster Presentation at the Society for Neuro-Oncology (SNO) 2020 Virtual Meeting
November 9th, 2020
VBI Vaccines Announces Third Quarter 2020 Financial Results and Provides Corporate Update
November 2nd, 2020
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at ID Week 2020™
October 26th, 2020
VBI Vaccines to Present at the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference
October 15th, 2020
VBI Vaccines Announces e-Poster Presentation at The Liver Meeting® 2020
October 8th, 2020
VBI Vaccines to Present at Upcoming Scientific Conferences
September 24th, 2020
VBI Vaccines Announces Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020
September 17th, 2020
VBI Vaccines to Present Additional Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM in an E-Poster at ESMO Virtual Congress 2020
September 14th, 2020
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at EASL 2020
August 31st, 2020

Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI

Sign Up NowArrow
Go top